Clinical Trail of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Upper Limb Bradykinesia in Parkinson' Disease' Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: high frequency-repetitive transcranial magnetic stimulation, sham stimulation.
- Who it may be relevant to
- Registry conditions: Parkinson's Disease (PD), Bradykinesia, Upper Limb Function. Basic parameters: 50 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Randomized Sham-Controlled Trial of High-frequency RTMS in the Treatment of Upper Limb Bradykinesia in Patients with Parkinson's Disease
Overview
A randomized, double-blind, sham-controlled unicenter clinical trial was used to investigate the effectiveness and neural mechanism of high-frequency repetitive transcranial magnetic stimulation in the treatment of upper limb bradykinesia in patients with Parkinson's disease.
Interventions
- Device high frequency-repetitive transcranial magnetic stimulation
rTMS involves the repeated application of magnetic pulses to specific areas of the brain. These pulses are delivered using a coil placed on the scalp, which generates a magnetic field that induces electrical currents in the brain tissue. - Device sham stimulation
The sham group receives 10 sessions of rTMS stimulation with a sham stimulation coil, which emits the same sound and vibration as the active coil but does not produce any induced electrical currents.
Primary outcome measures
- Unified Parkinson's Disease Rating Scale (MDS-UPDRS) [Time frame: 2 weeks and 4 weeks]
Secondary outcome measures (1)
- cortical activation detected by fNIRS [Time frame: 2 weeks and 4 weeks]
Eligibility criteria
Inclusion criteria
- Hoehn and Yahr (HY) stage 1-2
- Able to understand and cooperate with the study
- Predominantly characterized by bradykinesia
- Onset on the left side
Exclusion criteria
- Contraindications for TMS including DBS surgery, Ventriculoperitoneal shunt, etc
- Other neurological disorders
- Significant resting tremor, with MDS-UPDRS-III tremor score ≥3
- Resting threshold cannot be measured
- Received other TMS treatments within the last 3 months
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
China · 1 center
- Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine — Shanghai
Identifiers
NCT: NCT06641193 · XHEC-C-2024-125-2-2